請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22730
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳秀男 | |
dc.contributor.author | Chung-Lun Lu | en |
dc.contributor.author | 呂仲倫 | zh_TW |
dc.date.accessioned | 2021-06-08T04:26:07Z | - |
dc.date.copyright | 2010-03-10 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-02-22 | |
dc.identifier.citation | 參考文獻
1. Hansson, G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21, 1876-1890 (2001). 2. Chisolm, G.M. & Steinberg, D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28, 1815-1826 (2000). 3. Weisel, J.W. Structure of fibrin: impact on clot stability. J Thromb Haemost 5 Suppl 1, 116-124 (2007). 4. Collen, D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost 43, 77-89 (1980). 5. Kim, J.H. & Kim, Y.S. A fibrinolytic metalloprotease from the fruiting bodies of an edible mushroom, Armillariella mellea. Biosci Biotechnol Biochem 63, 2130-2136 (1999). 6. Kino, K., et al. Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. J Biol Chem 264, 472-478 (1989). 7. Kim, Y.S., et al. Dose dependency of earthworm powder on antithrombotic and fibrinolytic effects. Arch Pharm Res 21, 374-377 (1998). 8. Park, S.E., et al. Purification and characterization of a fibrinolytic protease from a culture supernatant of Flammulina velutipes mycelia. Biosci Biotechnol Biochem 71, 2214-2222 (2007). 9. Sasaki, K., et al. The transport of 125I-labeled human high molecular weight urokinase across the intestinal tract in a dog model with stimulation of synthesis and/or release of plasminogen activators. Blood 66, 69-75 (1985). 10. Sumi, H., et al. Plasma fibrinolysis after intraduodenal administration of urokinase in rats. Enzyme 33, 122-127 (1985). 11. Qiao, Y. & Wu, W. [Relationship between production input and secondary succession of earthworm population in salinity transforming region of north China--a case study in Quzhou County]. Ying Yong Sheng Tai Xue Bao 12, 414-416 (2001). 12. Mihara, H., et al. A novel fibrinolytic enzyme extracted from the earthworm, Lumbricus rubellus. Jpn J Physiol 41, 461-472 (1991). 13. Mine, Y., Wong, A.H.K. & Jiang, B. Fibrinolytic enzymes in Asian traditional fermented foods. Food Res Int 38, 243-250 (2005). 14. Gentry, P.A. Comparative aspects of blood coagulation. Vet J 168, 238-251 (2004). 15. Norris, L.A. Blood coagulation. Best Pract Res Clin Obstet Gynaecol 17, 369-383 (2003). 16. Wolberg, A.S. Thrombin generation and fibrin clot structure. Blood Rev 21, 131-142 (2007). 17. Takada, A., Takada, Y. & Urano, T. The physiological aspects of fibrinolysis. Thromb Res 76, 1-31 (1994). 18. Rijken, D.C. & Sakharov, D.V. Basic principles in thrombolysis: regulatory role of plasminogen. Thromb Res 103 Suppl 1, S41-49 (2001). 19. Ogston, D., Mc, D.G. & Fullerton, H.W. The influence of anxiety in tests of blood coagulability and fibrinolytic activity. Lancet 2, 521-523 (1962). 20. Levin, E.G., Marzec, U., Anderson, J. & Harker, L.A. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 74, 1988-1995 (1984). 21. Medved, L. & Nieuwenhuizen, W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 89, 409-419 (2003). 22. Carpenter, S.L. & Mathew, P. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 14, 1250-1254 (2008). 23. Haines, S.T. & Bussey, H.I. Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother 29, 892-905 (1995). 24. Ueshima, S. & Matsuo, O. Development of new fibrinolytic agents. Curr Pharm Des 12, 849-857 (2006). 25. Baker, W.F., Jr. Thrombolytic therapy. Clin Appl Thromb Hemost 8, 291-314 (2002). 26. Collen, D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nat Med 4, 279-284 (1998). 27. Collen, D. & Lijnen, H.R. Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost 2, 541-546 (2004). 28. Duffy, M.J. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 48, 1194-1197 (2002). 29. Giron, M.E., et al. Hemorrhagic, coagulant and fibrino(geno)lytic activities of crude venom and fractions from mapanare (Bothrops colombiensis) snakes. Comp Biochem Physiol C Toxicol Pharmacol 147, 113-121 (2008). 30. Strassburger, W., et al. Adaptation of plasminogen activator sequences to known protease structures. FEBS Lett 157, 219-223 (1983). 31. Banerjee, A., Chisti, Y. & Banerjee, U.C. Streptokinase--a clinically useful thrombolytic agent. Biotechnol Adv 22, 287-307 (2004). 32. Leonardi, A., Fox, J.W., Trampus-Bakija, A. & Krizaj, I. Ammodytase, a metalloprotease from Vipera ammodytes ammodytes venom, possesses strong fibrinolytic activity. Toxicon 49, 833-842 (2007). 33. Zhao, J., et al. Eisenia fetida Protease-III-1 Functions in both fibrinolysis and fibrogenesis. J Biomed Biotechnol 2007, 97654 (2007). 34. Ge, T., Sun, Z.J., Fu, S.H. & Liang, G.D. Cloning of thrombolytic enzyme (lumbrokinase) from earthworm and its expression in the yeast Pichia pastoris. Protein Expr Purif 42, 20-28 (2005). 35. Cheng, M.B., et al. Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme. J Control Release 129, 41-48 (2008). 36. Peng, Y., Yang, X. & Zhang, Y. Microbial fibrinolytic enzymes: an overview of source, production, properties, and thrombolytic activity in vivo. Appl Microbiol Biotechnol 69, 126-132 (2005). 37. Choi, N.S., Chang, K.T., Jae Maeng, P. & Kim, S.H. Cloning, expression, and fibrin (ogen)olytic properties of a subtilisin DJ-4 gene from Bacillus sp. DJ-4. FEMS Microbiol Lett 236, 325-331 (2004). 38. Ko, J.H., Yan, J.P., Zhu, L. & Qi, Y.P. Identification of two novel fibrinolytic enzymes from Bacillus subtilis QK02. Comp Biochem Physiol C-Toxicol & Pharmacol 137, 65-74 (2004). 39. Chitte, R.R. & Dey, S. Potent fibrinolytic enzyme from a thermophilic Streptomyces megasporus strain SD5. Lett Appl Microbiol 31, 405-410 (2000). 40. Kim, J.H. & Kim, Y.S. Characterization of a metalloenzyme from a wild mushroom, Tricholoma saponaceum. Biosci Biotechnol Biochem 65, 356-362 (2001). 41. Lee, S.Y., et al. Purification and characterization of fibrinolytic enzyme from cultured mycelia of Armillaria mellea. Protein Expr Purif 43, 10-17 (2005). 42. Hattori, M., Isomura, S., Yokoyama, E., Ujita, M. & Hara, A. Extracellular trypsin-like proteases produced by Cordyceps militaris. J Biosci Bioeng 100, 631-636 (2005). 43. Li, H.P., et al. A novel extracellular protease with fibrinolytic activity from the culture supernatant of Cordyceps sinensis: purification and characterization. Phytother Res 21, 1234-1241 (2007). 44. Matsubara, K., Hori, K., Matsuura, Y. & Miyazawa, K. A fibrinolytic enzyme from a marine green alga, Codium latum. Phytochemistry 52, 993-999 (1999). 45. Kim, W., et al. Purification and characterization of a fibrinolytic enzyme produced from Bacillus sp. strain CK 11-4 screened from Chungkook-Jang. Appl Environ Microbiol 62, 2482-2488 (1996). 46. Jeong, Y.K., et al. Purification of a fibrinolytic enzyme (myulchikinase) from pickled anchovy and its cytotoxicity to the tumor cell lines. Biotechnol Lett 26, 393-397 (2004). 47. Fujita, M., et al. Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan. Biochem Biophys Res Commun 197, 1340-1347 (1993). 48. Peng, Y., Huang, Q., Zhang, R.H. & Zhang, Y.Z. Purification and characterization of a fibrinolytic enzyme produced by Bacillus amyloliquefaciens DC-4 screened from douchi, a traditional Chinese soybean food. Comp Biochem Physiol B Biochem Mol Biol 134, 45-52 (2003). 49. Sullivan, R., Smith, J.E. & Rowan, N.J. Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. Perspect Biol Med 49, 159-170 (2006). 50. Ng, T.B. Peptides and proteins from fungi. Peptides 25, 1055-1073 (2004). 51. Choi, H.S. & Sa, Y.S. Fibrinolytic and antithrombotic protease from Ganoderma lucidum. Mycologia 92, 545-552 (2000). 52. Kim, J.S., et al. A fibrinolytic enzyme from the medicinal mushroom Cordyceps militaris. J Microbiol 44, 622-631 (2006). 53. Kim, J.S., et al. Purification and characterization of fibrinolytic metalloprotease from Perenniporia fraxinea mycelia. Mycol Res 112, 990-998 (2008). 54. Block, S.S., Stearns, T.W., Stephens, R.L. & Mccandless, R.F.J. Mushroom mycelium - experiments with submerged culture. J Agri Food Chem 1, 890-893 (1953). 55. Litchfield, J.H., Davidson, R.S. & Overbeck, R.C. Factors affecting growth of morel mushroom mycelium in submerged culture. J Agri Food Chem 11, 158-& (1963). 56. Papagianni, M. Fungal morphology and metabolite production in submerged mycelial processes. Biotechnol Adv 22, 189-259 (2004). 57. Watling, R. & Sweeney, J. Observations on Schizophyllum commune Fries. Res Commun Chem Pathol Pharmacol 3, 214-226 (1972). 58. Aletor, V.A. Compositional studies on edible tropical species of mushrooms. Food Chem 54, 265-268 (1995). 59. Hao, L.M., et al. Optimization of effect factors for mycelial growth and exopolysaccharide production by Schizophyllum commune. Appl Biochem Biotechnol (2009). 60. Desrochers, M., Jurasek, L. & Paice, M.G. High production of beta-glucosidase in Schizophyllum commune: Isolation of the enzyme and effect of the culture filtrate on cellulose hydrolysis. Appl Environ Microbiol 41, 222-228 (1981). 61. Leathers, T.D., Nunnally, M.S. & Price, N.P. Co-production of schizophyllan and arabinoxylan from corn fiber. Biotechnol Lett 28, 623-626 (2006). 62. Spanikova, S. & Biely, P. Glucuronoyl esterase--novel carbohydrate esterase produced by Schizophyllum commune. FEBS Lett 580, 4597-4601 (2006). 63. Kumari, M., Survase, S.A. & Singhal, R.S. Production of schizophyllan using Schizophyllum commune NRCM. Bioresour Technol 99, 1036-1043 (2008). 64. Willick, G.E., Morosoli, R., Seligy, V.L., Yaguchi, M. & Desrochers, M. Extracellular proteins secreted by the basidiomycete Schizophyllum commune in response to carbon source. J Bacteriol 159, 294-299 (1984). 65. Fukushima, Y., Itoh, H., Fukase, T. & Motai, H. Stimulation of protease production by aspergillus-oryzae with oils in continuous culture. Appl Microbiol Biotechnol 34, 586-590 (1991). 66. Yoon, S.J., et al. The nontoxic mushroom Auricularia auricula contains a polysaccharide with anticoagulant activity mediated by antithrombin. Thromb Res 112, 151-158 (2003). 67. Martinichen-Herrero, J.C., Carbonero, E.R., Sassaki, G.L., Gorin, P.A. & Iacomini, M. Anticoagulant and antithrombotic activities of a chemically sulfated galactoglucomannan obtained from the lichen Cladonia ibitipocae. Int J Biol Macromol 35, 97-102 (2005). 68. Okamura-Matsui, T., et al. Characteristics of a cheese-like food produced by fermentation of the mushroom Schizophyllum commune. J Biosci Bioeng 92, 30-32 (2001). 69. Gallimore, M.J., Harris, S.L., Tappenden, K.A., Winter, M. & Jones, D.W. Urokinase induced fibrinolysis in thromboelastography: a model for studying fibrinolysis and coagulation in whole blood. J Thromb Haemost 3, 2506-2513 (2005). 70. Landskroner, K.A., Olson, N.C. & Jesmok, G.J. Thromboelastography measurements of whole blood from factor VIII-deficient mice supplemented with rFVIII. Haemophilia 11, 346-352 (2005). 71. Hartert, H. Blutgerinnungsstudienmit der Thrombelastographie, einemneuen Untersuchungsverfahren. Klin Wochenschr 26, 577-583 (1948). 72. Mallett, S.V. & Cox, D.J. Thrombelastography. Br J Anaesth 69, 307-313 (1992). 73. Plump, A.S., et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343-353 (1992). 74. Knowles, J.W., et al. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 105, 451-458 (2000). 75. Mahley, R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630 (1988). 76. Krege, J.H., Hodgin, J.B., Hagaman, J.R. & Smithies, O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25, 1111-1115 (1995). 77. Zhang, S.H., Reddick, R.L., Piedrahita, J.A. & Maeda, N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258, 468-471 (1992). 78. Nakashima, Y., Plump, A.S., Raines, E.W., Breslow, J.L. & Ross, R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14, 133-140 (1994). 79. Paigen, B., Morrow, A., Holmes, P.A., Mitchell, D. & Williams, R.A. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68, 231-240 (1987). 80. Reddick, R.L., Zhang, S.H. & Maeda, N. Atherosclerosis in mice lacking Apo-E - evaluation of lesional development and progression (Vol 14, Pg 141, 1994). Arterioscler Thromb 14, 839-839 (1994). 81. Grover, P.K. & Ryall, R.L. Critical appraisal of salting-out and its implications for chemical and biological sciences. Chem Rev 105, 1-10 (2005). 82. Yamamoto, J., Yamada, K., Naemura, A., Yamashita, T. & Arai, R. Testing various herbs for antithrombotic effect. Nutrition 21, 580-587 (2005). 83. Doljak, B., et al. Screening for selective thrombin inhibitors in mushrooms. Blood Coagul Fibrinolysis 12, 123-128 (2001). 84. Astrup, T. & Mullertz, S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 40, 346-351 (1952). 85. Hummel, B.C.W., Schor, J.M., Buck, F.F., Boggiano, E. & Derenzo, E.C. Quantitative enzymic assay of human plasminogen and plasmin with azocasein as substrate. Anal Biochem 11, 532-547 (1965). 86. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254 (1976). 87. Shin, H.H. & Choi, H.S. Purification and characterization of cysteine protease from Pleurotus ostreatus. Biosci Biotechnol Biochem 62, 1416-1418 (1998). 88. Shih, I.L., Tsai, K.L. & Hsieh, C. Effects of culture conditions on the mycelial growth and bioactive metabolite production in submerged culture of Cordyceps militaris. Biochem Eng J 33, 193-201 (2007). 89. Fang, H.H. & Liu, H. Effect of pH on hydrogen production from glucose by a mixed culture. Bioresour Technol 82, 87-93 (2002). 90. Lewis, W.G., Basford, J.M. & Walton, P.L. Specificity and inhibition studies of Armillaria mellea protease. Biochim Biophys Acta 522, 551-560 (1978). 91. Nonaka, T., Ishikawa, H., Tsumuraya, Y., Hashimoto, Y. & Dohmae, N. Characterization of a thermostable lysine-specific metalloendopeptidase from the fruiting bodies of a basidiomycete, Grifola frondosa. J Biochem 118, 1014-1020 (1995). 92. Wasser, S.P. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 60, 258-274 (2002). 93. Collen, D. & Lijnen, H.R. Thrombolytic agents. Thromb Haemost 93, 627-630 (2005). 94. Vig, S., Chitolie, A., Bevan, D.H., Halliday, A. & Dormandy, J. Thromboelastography: a reliable test? Blood Coagul Fibrinolysis 12, 555-561 (2001). 95. Mosesson, M.W. Fibrinogen gamma chain functions. J Thromb Haemost 1, 231-238 (2003). 96. Guo, Y.W., et al. Cloning and functional expression of the mucrosobin protein, a beta-fibrinogenase of Trimeresurus mucrosquamatus (Taiwan Habu). Protein Expr Purif 23, 483-490 (2001). 97. Pinto, A.F., Dobrovolski, R., Veiga, A.B. & Guimaraes, J.A. Lonofibrase, a novel alpha-fibrinogenase from Lonomia obliqua caterpillars. Thromb Res 113, 147-154 (2004). 98. Choi, H.S. & Sa, Y.S. Fibrinolytic and antithrombotic protease from Spirodela polyrhiza. Biosci Biotechnol Biochem 65, 781-786 (2001). 99. Katori, N., Tanaka, K.A., Szlam, F. & Levy, J.H. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg 100, 1781-1785 (2005). 100. Jen, C.L., et al. Serum alanine aminotransferase level, correlated factors, and risk of liver diseases: A long-term follow-up study. J Hepatol 44, S173-S173 (2006). 101. Nevin, K.G. & Vijayammal, P.L. Effect of Aerva lanata against hepatotoxicity of carbon tetrachloride in rats. Environ Toxicol Pharmacol 20, 471-477 (2005). 102. Ross, R. Atherosclerosis--an inflammatory disease. N Engl J Med 340, 115-126 (1999). 103. Nunnari, J.J., Zand, T., Joris, I. & Majno, G. Quantitation of oil red O staining of the aorta in hypercholesterolemic rats. Exp Mol Pathol 51, 1-8 (1989). 104. Frokjaer, S. & Otzen, D.E. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 4, 298-306 (2005). 105. Mustata, G. & Dinh, S.M. Approaches to oral drug delivery for challenging molecules. Crit Rev Ther Drug Carrier Syst 23, 111-135 (2006). 106. Mahato, R.I., Narang, A.S., Thoma, L. & Miller, D.D. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20, 153-214 (2003). 107. Lin, J.D., et al. Serum glutamic-oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) levels in children and adolescents with intellectual disabilities. Res Dev Disabil 31, 172-177. 108. Subramoniam, A., Evans, D.A., Rajasekharan, S. & Pushpangadan, P. Hepatoprotective activity of Trichopus zeylanicus extract against paracetamol-induced hepatic damage in rats. Indian J Exp Biol 36, 385-389 (1998). 109. Adams, J.E. Clinical application of markers of cardiac injury: basic concepts and new considerations. Clinica Chimica Acta 284, 127-134 (1999). 110. Wahrburg, U., Martin, H., Sandkamp, M., Schulte, H. & Assmann, G. Comparative effects of a recommended lipid-lowering diet vs a diet rich in monounsaturated fatty acids on serum lipid profiles in healthy young adults. Am J Clin Nutr 56, 678-683 (1992). 111. Shimokawa, H. & Vanhoutte, P.M. Dietary cod-liver oil improves endothelium-dependent responses in hypercholesterolemic and atherosclerotic porcine coronary arteries. Circulation 78, 1421-1430 (1988). 112. Shimokawa, H. & Vanhoutte, P.M. Dietary omega 3 fatty acids and endothelium-dependent relaxations in porcine coronary arteries. Am J Physiol 256, H968-973 (1989). 113. Fukushima, M., Ohashi, T., Fujiwara, Y., Sonoyama, K. & Nakano, M. Cholesterol-lowering effects of maitake (Grifola frondosa) fiber, shiitake (Lentinus edodes) fiber, and enokitake (Flammulina velutipes) fiber in rats. Exp Biol Med (Maywood) 226, 758-765 (2001). 114. Medel, R., Monteith, S.J., Crowley, R.W. & Dumont, A.S. A review of therapeutic strategies for the management of cerebral venous sinus thrombosis. Neurosurg Focus 27, E6 (2009). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22730 | - |
dc.description.abstract | 裂褶菌(Schizophyllum commune)是一廣泛分布於世界各地的菇蕈種類,並於傳統醫學中,因其富含蛋白質與具有抗血栓療效的特性而受到重視。近年來,已發展國家中的人們對於預防以及治療血栓性疾病之研究,莫不投注以相當高的關注,而同時科學家們於眾多研究中,也希望再找到安全性更高與更有效的抗血栓藥物,來預防與治療血栓性疾病。本研究利用橫掃式分子過濾以及快速液相層析技術,自醱酵培養的裂褶菌培養液中,純化一分子量為21.32 kDa,具備溶解纖維蛋白活性的新穎溶纖蛋白酶(fibrinolytic protease),並發現於pH 5.0與溫度45°C時其具有最佳的酵素活性,且其受EDTA抑制以及可受鎂離子刺激提升活性。研究亦發現,此蛋白酶亦具有溶解纖維蛋白原活性與不具誘發人類溶纖維蛋白酶原活化的作用,並於血液血栓彈力圖分析中,也確被證實具有降低血液凝固強度與纖溶作用過度的現象,除此之外,由對小鼠動脈粥狀硬化病症發生過程之研究得知,裂褶菌醱酵產物具有降低血栓塞形成,保護肝臟、心臟以及其他組織器官受到損害之明顯效果 | zh_TW |
dc.description.abstract | Schizophyllum commune, a widely distributed medical mushroom, is valued by rich in protein content and with anti-thrombotic activity in traditional medicine. Prevention and therapy of thrombotic diseases have attracted much attention in people whom lived in developed countries during recent years. Investigators have been looking for safer and more effective thrombolytic agents for therapy of thrombotic diseases. In this study, a fibrinolytic activity protease was purified from S. commune fermented broth by cross-flow filtration and FPLC. The properties were characterized and showed 21.32 kDa in molecular mass and optimal activity at pH 5.0 and 45°C. The fibrinolytic activities which upregulated by magnesium and inhibited by EDTA were proven. Subsequently, the protease was found failure in plasminogen activation, and studied in animal experiments. As the thromboelastography result showed, S. commune fibrinolytic protease can reduce the strength of blood clot and prevent excessive systemic fibrinolysis. Moreover, the protein extract from fermented S. commune was proven with innovative anti-thrombotic activity and protection effects of internal organs damage in atherosclerosis pathogenesis study. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T04:26:07Z (GMT). No. of bitstreams: 1 ntu-99-D91225009-1.pdf: 5434188 bytes, checksum: 81d9461a2a99e02ef6c6923948084df4 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 總 目 錄
頁次 口試委員會審定書……………………………..………………………..……….…….. i 謝辭………………………………………………………….………………….……… ii 中文摘要……………………………………………………………………….……… iii 英文摘要……………………………………………………………………….……… iv 總目錄…………………………………………………………...……..………………..v 目錄……………………………………………………………………………………..vi 圖目錄……………………………………………………………………………..……ix 表目錄…………………………………………………………………………….…….xi 目 錄 第一章 文獻整理-----------------------------------------------------------------------------頁次 1. 1 前言………….……………………………………………………………….1 1. 2 血液凝固與纖溶作用…………..……………………………………………3 1. 3 血栓與抗血栓用藥…………………………………………..………………5 1. 4 溶纖活性蛋白酶………..……………………………………………………7 1. 5 裂褶菌(Schizophyllum commune)與其產物之應用………..………………..9 1. 6 血液血栓彈力圖譜(thromboelastography)分析...………………………….10 1. 7 ApoE-/-基因剔除小鼠與動脈粥狀硬化症模式生物....................................13 第二章 裂褶菌液態醱酵培養及產物分離-----------------------------------------------頁次 2. 1 前言…..………….………………………………………………………….15 2. 2 菌種與藥品設備…..………………..………………………………………15 2. 3 實驗方法與步驟……..…..…………………………………………………16 2. 4 結果與討論…………………………………………………………………16 第三章 裂褶菌溶纖蛋白酶的純化分離--------------------------------------------------頁次 3. 1 前言……………………………………………………………………….19 3. 2 藥品設備……....…………………..………………………………………19 3. 3 實驗步驟與方法………..…………………………………………………..20 3. 4 結果…………………………………………………………………………23 3. 5 討論…………………………………………………………………………29 第四章 裂褶菌溶纖蛋白酶特性分析--------------------------------------------------頁次 4. 1 前言……………………………………………………………………….31 4. 2 藥品設備……....…………………..………………………………………31 4. 3 實驗步驟與方法………..…………………………………………………..32 4. 4 結果…………………………………………………………………………33 4. 5 討論…………………………………………………………………………39 第五章 裂褶菌溶纖蛋白酶對血液凝固因子作用--------------------------------------頁次 5. 1 前言……………………………………………………………………….42 5. 2 藥品設備與實驗動物……..………..………………………………………43 5. 3 實驗步驟與方法………..…………………………………………………..43 5. 4 結果…………………………………………………………………………45 5. 5 討論…………………………………………………………………………49 第六章 裂褶菌蛋白對ApoE基因剔除小鼠血栓形成與生理生化影響------------頁次 6. 1 前言……………………………………………………………………….52 6. 2 藥品設備與實驗動物……..………..………………………………………53 6. 3 實驗步驟與方法………..…………………………………………………..53 6. 4 結果…………………………………………………………………………56 6. 5 討論…………………………………………………………………………62 第七章 總結-----------------------------------------------------------------------------------頁次 7. 1 結論……………………………………………………………………….67 7. 2 未來研究…………………..………..………………………………………68 7. 3 論文發表………………..…………………………………………………..68 參考文獻……………………………………………………………………………….69 附錄…………………………………………………………………………….………81 圖 目 錄 第一章 文獻整理-----------------------------------------------------------------------------頁次 圖1-1 纖維蛋白聚集與纖溶作用……………………………………………......4 圖1-2 纖溶作用機制……………………………………………………………..4 圖1-3 Thromboelastograpy®血液血栓彈力圖譜分析儀………………….….....11 圖1-4 血栓彈力圖譜……………………………………………………………12 圖1-5 ApoE-/-基因剔除小鼠罹患動脈粥狀硬化症後心血管損傷時程………13 圖1-6 ApoE-/-基因剔除小鼠主動脈弧發生動脈粥狀硬化病灶位置..…..……14 第二章 裂褶菌液態醱酵培養及產物分離-----------------------------------------------頁次 圖2-1 裂褶菌醱酵培養液之產物萃取…………………………...…….…..…..17 第三章 裂褶菌溶纖蛋白酶的純化分離--------------------------------------------------頁次 圖3-1 裂褶菌培養液蛋白質層析與人工纖維蛋白盤活性測試...................24,25 圖3-2 裂褶菌培養液蛋白質電泳分析................................................................26 圖3-3 裂褶菌溶纖蛋白酶與人類溶纖蛋白酶活性比較……………...…….....26 圖3-4 膠體過濾層析檢定裂褶菌溶纖蛋白酶分子量……………………… ...28 第四章 裂褶菌溶纖蛋白酶特性分析--------------------------------------------------頁次 圖4-1 裂褶菌溶纖蛋白酶二維電泳(2D- Electrophoresis)分析..........................34 圖4-2 裂褶菌溶纖蛋白酶醣類染色鑑定............................................................35 圖4-3 蛋白酶抑制物與二價金屬離子對裂褶菌溶纖蛋白酶活性影響………36 圖4-4 酸鹼度與溫度對裂褶菌溶纖蛋白酶活性影響…………………...…37,38 第五章 裂褶菌溶纖蛋白酶對血液凝固因子作用--------------------------------------頁次 圖5-1 裂褶菌溶纖蛋白酶對人類纖維蛋白原分解活性分析............................46 圖5-2 裂褶菌溶纖蛋白酶對人類溶纖維蛋白酶原刺激作用分析....................47 圖5-3 裂褶菌溶纖蛋白酶對人類溶纖維蛋白酶原刺激--人工瓊脂盤分析…..47 圖5-4 裂褶菌溶纖蛋白酶對大鼠血液血栓彈力圖之影響………..…....……..49 第六章 裂褶菌蛋白對ApoE基因剔除小鼠血栓形成與生理生化影響------------頁次 圖6-1 裂褶菌蛋白對小鼠主動脈弧纖維斑塊堆積之影響................................57 圖6-2 裂褶菌蛋白對小鼠肝臟轉胺酵素之影響................................................58 圖6-3 裂褶菌蛋白對小鼠血清脂質之影響……………………………………61 圖6-4 裂褶菌蛋白對小鼠血清蛋白比值之影響………………...........……….62 表 目 錄 第一章 文獻整理-----------------------------------------------------------------------------頁次 表1-1 菇蕈類溶纖維蛋白酶與抗血栓作用……………………….…………….8 第二章 裂褶菌液態醱酵培養及產物分離-----------------------------------------------頁次 無 第三章 裂褶菌溶纖蛋白酶的純化分離--------------------------------------------------頁次 表3-1 裂褶菌溶纖蛋白酶純化效率以及獲取率................................................27 第四章 裂褶菌溶纖蛋白酶特性分析--------------------------------------------------頁次 表4-1 裂褶菌溶纖蛋白酶與其他菇蕈類溶纖維蛋白酶N端序列比較.............38 表4-2 裂褶菌溶纖蛋白酶與金屬型內切胜肽酶(metalloendopeptidase, MEPs) N端序列比較……………………………………………………….……39 第五章 裂褶菌溶纖蛋白酶對血液凝固因子作用--------------------------------------頁次 表5-1裂褶菌溶纖蛋白酶對大鼠血液血栓彈力圖值之影響..............................48 第六章 裂褶菌蛋白對ApoE基因剔除小鼠血栓形成與生理生化影響------------頁次 無 第七章 總結-----------------------------------------------------------------------------------頁次 無 | |
dc.language.iso | zh-TW | |
dc.title | 液態醱酵培養裂褶菌之溶纖活性研究與應用 | zh_TW |
dc.title | The Study and Application of Fermented Schizophyllum commune Fibrinolytic Activity | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 李國誥,沈士新,林清龍,秦宗顯,林承箕 | |
dc.subject.keyword | 菇蕈類,溶纖蛋白酶,溶纖蛋白活性,抗血栓形成,裂褶菌, | zh_TW |
dc.subject.keyword | mushroom,fibrinolytic protease,fibrinolytic activity,anti-thrombotic,Schizophyllum commune, | en |
dc.relation.page | 81 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2010-02-22 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 漁業科學研究所 | zh_TW |
顯示於系所單位: | 漁業科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 5.31 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。